

## STOP-DWI NY REGIONAL TRAINING OPPORTUNITY

### Webinar Training

#### Update on illicit fentanyl use and its effect on driving

By Barry K Logan PhD, F-ABFT

Date:

September 30, 2024

Time: 1 pm- 3 pm

**Registration/sign-in  
begins at 12:45 pm**

Location: Zoom

To Register:

[https://us02web.zoom.us/webinar/register/WN\\_3S8YzsRAT-T-uYYWRGIVlpQ](https://us02web.zoom.us/webinar/register/WN_3S8YzsRAT-T-uYYWRGIVlpQ)

Contact:

Sheryl Hutton

[Hutton.sheryl@yahoo.com](mailto:Hutton.sheryl@yahoo.com)

315-723-1189

No training credits  
are available.

The NY State STOP-DWI Foundation, Inc., through funding from the NYS Governor's Traffic Safety Committee, is pleased to sponsor a statewide training to benefit local STOP-DWI efforts in New York State. This seminar is free of charge to all STOP-DWI partners engaged in preventing impaired driving.

#### Update on illicit fentanyl use and its effect on driving

Opioids have been increasing in terms of their prevalence in impaired driving cases especially over the last six years since fentanyl began to exceed heroin in the illicit drug supply. This presentation will review the pharmacological and physiological effects of opioids, including the effects of opioids on driving, the impairment profile for narcotic analgesics based on DRE indicators and SFST performance, and how to read the toxicology results. Illicit use and abuse of fentanyl grew as the opioid crisis evolved from prescription opioids like hydrocodone and oxycodone, to heroin, fentanyl and then fentanyl analogs like carfentanil which is still around today. There have also been several novel synthetic opioids with unfamiliar names like bromphine, and isotonitazene that are contributing to opioid impairment. The picture gets further complicated by the interactions of fentanyl with xylazine used a cutting agent. Xylazine is a CNS-depressant approved for use in veterinary medicine as a tranquilizer. When used in combination with fentanyl, it can increase the severity and chance of sedation, muscle relaxation, bradycardia, and respiratory depression. Over the years, blood fentanyl concentrations have been documented to be increasing highlighting the importance of understanding how drug tolerance affects drug users but doesn't eliminate impairment even in tolerant subjects. Staying current with trends in novel opioid use helps prepare DRE's and Toxicologists for court and testimony.

#### Barry K Logan PhD, F-ABFT

Dr. Barry Logan is Chief Scientist and Senior Vice President for Forensic Sciences at NMS Labs, an international reference lab providing forensic toxicology and chemistry services to public and private crime labs, coroners and medical examiners and death investigators throughout the world. He also serves as Executive Director at the non-profit Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieder's Family Foundation in Willow Grove, Pennsylvania.

Dr. Logan holds academic appointments at Arcadia, Thomas Jefferson and Indiana Universities in the United States, and is a Fellow of the American Board of Forensic Toxicologists (ABFT). Over his career, he has authored or co-authored over 200 publications, and has made over 700 presentations in topics in forensic toxicology and analytical chemistry, including work on postmortem and human performance toxicology. In 2023, he was recognized as the most highly cited author in the field of forensic toxicology in the United States. His current research priorities are focused on new drug trends, the opioid crisis, rapid reporting of drug mortality data, and the analytical and interpretive toxicology and chemistry of novel psychoactive substances, founding [www.NPSDiscovery.org](http://www.NPSDiscovery.org) in 2018.